vs
卡彭特科技（CRS）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
卡彭特科技的季度营收约是Royalty Pharma plc的1.3倍（$811.5M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 17.2%，领先17.2%），卡彭特科技同比增速更快（11.6% vs 4.8%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs 0.8%）
卡彭特科技是全球特种合金材料供应商，主营不锈钢、耐腐蚀镍、铜、钛合金及3D增材制造用粉末合金的研发、生产与分销。2018财年其营收分布为：航空航天与国防占55%，工业与消费品占17%，医疗占8%，交通、能源各占7%，分销业务占6%。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
CRS vs RPRX — 直观对比
营收规模更大
CRS
是对方的1.3倍
$622.0M
营收增速更快
CRS
高出6.8%
4.8%
净利率更高
RPRX
高出17.2%
17.2%
两年增速更快
RPRX
近两年复合增速
0.8%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $811.5M | $622.0M |
| 净利润 | $139.6M | $214.2M |
| 毛利率 | 31.0% | — |
| 营业利润率 | 23.0% | 62.4% |
| 净利率 | 17.2% | 34.4% |
| 营收同比 | 11.6% | 4.8% |
| 净利润同比 | 46.3% | 2.9% |
| 每股收益（稀释后） | $2.77 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRSRPRX
| Q1 26 | $811.5M | — | ||
| Q4 25 | $728.0M | $622.0M | ||
| Q3 25 | $733.7M | $609.3M | ||
| Q2 25 | $755.6M | $578.7M | ||
| Q1 25 | $727.0M | $568.2M | ||
| Q4 24 | $676.9M | $593.6M | ||
| Q3 24 | $717.6M | $564.7M | ||
| Q2 24 | $798.7M | $537.3M |
净利润CRSRPRX
| Q1 26 | $139.6M | — | ||
| Q4 25 | $105.3M | $214.2M | ||
| Q3 25 | $122.5M | $288.2M | ||
| Q2 25 | $111.7M | $30.2M | ||
| Q1 25 | $95.4M | $238.3M | ||
| Q4 24 | $84.1M | $208.2M | ||
| Q3 24 | $84.8M | $544.0M | ||
| Q2 24 | $93.6M | $102.0M |
毛利率CRSRPRX
| Q1 26 | 31.0% | — | ||
| Q4 25 | 30.0% | — | ||
| Q3 25 | 29.5% | — | ||
| Q2 25 | 28.3% | — | ||
| Q1 25 | 27.6% | — | ||
| Q4 24 | 26.2% | — | ||
| Q3 24 | 24.6% | — | ||
| Q2 24 | 23.9% | — |
营业利润率CRSRPRX
| Q1 26 | 23.0% | — | ||
| Q4 25 | 21.3% | 62.4% | ||
| Q3 25 | 20.9% | 70.1% | ||
| Q2 25 | 20.1% | 36.3% | ||
| Q1 25 | 19.0% | 94.0% | ||
| Q4 24 | 17.6% | 60.9% | ||
| Q3 24 | 15.8% | — | ||
| Q2 24 | 13.6% | 50.2% |
净利率CRSRPRX
| Q1 26 | 17.2% | — | ||
| Q4 25 | 14.5% | 34.4% | ||
| Q3 25 | 16.7% | 47.3% | ||
| Q2 25 | 14.8% | 5.2% | ||
| Q1 25 | 13.1% | 41.9% | ||
| Q4 24 | 12.4% | 35.1% | ||
| Q3 24 | 11.8% | 96.3% | ||
| Q2 24 | 11.7% | 19.0% |
每股收益（稀释后）CRSRPRX
| Q1 26 | $2.77 | — | ||
| Q4 25 | $2.09 | $0.49 | ||
| Q3 25 | $2.43 | $0.67 | ||
| Q2 25 | $2.21 | $0.07 | ||
| Q1 25 | $1.88 | $0.55 | ||
| Q4 24 | $1.66 | $0.46 | ||
| Q3 24 | $1.67 | $1.21 | ||
| Q2 24 | $1.85 | $0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $294.8M | $618.7M |
| 总债务越低越好 | $690.4M | $9.0B |
| 股东权益账面价值 | $2.1B | $9.7B |
| 总资产 | $3.7B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.33× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资CRSRPRX
| Q1 26 | $294.8M | — | ||
| Q4 25 | $231.9M | $618.7M | ||
| Q3 25 | $208.0M | $938.9M | ||
| Q2 25 | $315.5M | $631.9M | ||
| Q1 25 | $151.5M | $1.1B | ||
| Q4 24 | $162.1M | $929.0M | ||
| Q3 24 | $150.2M | $950.1M | ||
| Q2 24 | $199.1M | $1.8B |
总债务CRSRPRX
| Q1 26 | $690.4M | — | ||
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B |
股东权益CRSRPRX
| Q1 26 | $2.1B | — | ||
| Q4 25 | $2.0B | $9.7B | ||
| Q3 25 | $1.9B | $9.6B | ||
| Q2 25 | $1.9B | $9.5B | ||
| Q1 25 | $1.8B | $9.8B | ||
| Q4 24 | $1.7B | $10.3B | ||
| Q3 24 | $1.7B | $10.3B | ||
| Q2 24 | $1.6B | $9.8B |
总资产CRSRPRX
| Q1 26 | $3.7B | — | ||
| Q4 25 | $3.5B | $19.6B | ||
| Q3 25 | $3.4B | $19.3B | ||
| Q2 25 | $3.5B | $18.3B | ||
| Q1 25 | $3.4B | $17.6B | ||
| Q4 24 | $3.3B | $18.2B | ||
| Q3 24 | $3.3B | $18.0B | ||
| Q2 24 | $3.3B | $17.7B |
负债/权益比CRSRPRX
| Q1 26 | 0.33× | — | ||
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $124.8M | — |
| 自由现金流率自由现金流/营收 | 15.4% | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 3.86× |
| 过去12个月自由现金流最近4个季度 | $407.5M | — |
8季度趋势，按日历期对齐
经营现金流CRSRPRX
| Q1 26 | — | — | ||
| Q4 25 | $132.2M | $827.1M | ||
| Q3 25 | $39.2M | $702.6M | ||
| Q2 25 | $258.1M | $364.0M | ||
| Q1 25 | $74.2M | $596.1M | ||
| Q4 24 | $67.9M | $742.5M | ||
| Q3 24 | $40.2M | $703.6M | ||
| Q2 24 | $169.5M | $658.2M |
自由现金流CRSRPRX
| Q1 26 | $124.8M | — | ||
| Q4 25 | $85.9M | — | ||
| Q3 25 | $-3.4M | — | ||
| Q2 25 | $200.2M | — | ||
| Q1 25 | $34.0M | — | ||
| Q4 24 | $38.6M | — | ||
| Q3 24 | $13.3M | — | ||
| Q2 24 | $141.8M | — |
自由现金流率CRSRPRX
| Q1 26 | 15.4% | — | ||
| Q4 25 | 11.8% | — | ||
| Q3 25 | -0.5% | — | ||
| Q2 25 | 26.5% | — | ||
| Q1 25 | 4.7% | — | ||
| Q4 24 | 5.7% | — | ||
| Q3 24 | 1.9% | — | ||
| Q2 24 | 17.8% | — |
资本支出强度CRSRPRX
| Q1 26 | — | — | ||
| Q4 25 | 6.4% | — | ||
| Q3 25 | 5.8% | — | ||
| Q2 25 | 7.7% | — | ||
| Q1 25 | 5.5% | — | ||
| Q4 24 | 4.3% | — | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 3.5% | — |
现金转化率CRSRPRX
| Q1 26 | — | — | ||
| Q4 25 | 1.26× | 3.86× | ||
| Q3 25 | 0.32× | 2.44× | ||
| Q2 25 | 2.31× | 12.06× | ||
| Q1 25 | 0.78× | 2.50× | ||
| Q4 24 | 0.81× | 3.57× | ||
| Q3 24 | 0.47× | 1.29× | ||
| Q2 24 | 1.81× | 6.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CRS
| Aerospace and Defense | $435.6M | 54% |
| Surcharge revenue | $155.9M | 19% |
| Industrial and Consumer | $78.1M | 10% |
| Medical | $51.7M | 6% |
| Energy | $50.5M | 6% |
| Distribution | $20.4M | 3% |
| Transportation | $19.3M | 2% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
